Balchem Corp Q3 2025 Earnings Call Highlights

Balchem Corporation's Q3 2025 Earnings Call Transcript

At the beginning of the call, the operator welcomed all participants and reminded them to keep their lines muted to avoid background noise. The call was followed by a question and answer session after the speakers’ remarks. Carl Martin Bengtsson, CFO of Balchem Corporation, began the call by acknowledging the attendees and reading the forward-looking statements.

Forward-Looking Statements and Non-GAAP Measures

The company’s statements during the call that are not historical facts are considered forward-looking. These statements come with the risk that actual results may differ from expectations. The company has identified various factors that could lead to such differences, including market conditions, regulatory changes, and other risks outlined in its recent financial reports. Balchem assumes no obligation to update these forward-looking statements. Additionally, the call included non-GAAP financial measures, which can be found in the earnings release for reconciliation purposes.

CEO’s Remarks on Financial Performance

Theodore Lee Harris, Chairman, President, and CEO of Balchem Corporation, expressed his satisfaction with the company's performance in 2025. He highlighted the strong performance of the company’s unique portfolio of specialty nutrients and delivery systems, as well as the favorable trends in the food and nutrition markets. The company achieved record quarterly consolidated sales, adjusted EBITDA, adjusted net earnings, and adjusted EPS, with year-over-year growth in all three reporting segments. This marks the twenty-fifth consecutive quarter of quarterly year-over-year growth in adjusted EBITDA for Balchem Corporation.

Harris thanked the entire team for their contributions and acknowledged the challenging market environment over the past 25 quarters. He also discussed the evolving global trade situation and the impact of new scientific research supporting the company’s nutrients. The company continues to see healthy demand across most of its end markets.

Segment Performance

The Human Nutrition and Health segment continued to perform extremely well, driven by strong demand for minerals, nutrients, vitamins, and food ingredients. The Animal Nutrition and Health segment delivered another quarter of year-over-year growth, with improved demand in both monogastric and ruminant businesses. The Specialty Products segment saw strong performance in both Performance Gases and Plant Nutrition businesses, driven by higher demand and successful geographic expansion.

On a consolidated basis, the company delivered strong growth on both the top and bottom lines while generating robust free cash flow. The outlook for the remainder of the year remains positive, with the company well-positioned to manage through the current global trade environment.

Scientific Research and Marketing Initiatives

Balchem has made progress in its scientific clinical research pipeline, which supports the Human Nutrition and Health segment. The company continues to invest in the science behind its brands, such as VitaCholine, K2Vital, OptiMSM, and Albion Minerals. One notable study published recently involved a blood-based test to measure choline status in humans, which promises to help identify choline deficiency and support supplementation efforts.

In terms of marketing, the company has expanded its reach through initiatives like the Real Science Exchange platform, which has grown into a leading industry resource. Balchem has also partnered with Progressive Dairy Magazine to introduce the Real Producer Exchange for practical insights for dairy farmers. The company is set to expand into the companion animal sector with new webinars and podcasts.

Financial Highlights

Balchem reported record quarterly consolidated revenue of $268 million, an 11.5% increase compared to the prior year. GAAP earnings from operations reached $55 million, up 13.7% from the previous year. Consolidated net income closed at $40 million, an increase of 19.1%. On an adjusted basis, the company delivered record quarterly adjusted EBITDA of $71 million, an 11% increase from the prior year.

The record quarterly adjusted net earnings were $44 million, an increase of 19.1% from the prior year, translating to $1.35 per diluted share. Cash flows from operations were $66 million, with free cash flow of $51 million, and the company ended the quarter with $65 million in cash.

Segment-Specific Results

The Human Nutrition and Health segment generated record sales of $174 million, an increase of 14.3% from the prior year. The segment also delivered record quarterly earnings from operations of $41 million, up 14.8% from the previous year. The Animal Nutrition and Health segment reported quarterly sales of $56 million, an increase of 6.6% compared to the prior year, with earnings from operations of $4 million, up 5.2% from the previous year. The Specialty Products segment delivered quarterly sales of $36 million, an increase of 7.5% compared to the prior year, with earnings from operations of $12 million, up 9.7% from the previous year.

Closing Remarks

Theodore Lee Harris concluded the call by reiterating the company’s confidence in its long-term growth outlook. The company has demonstrated its ability to deliver results in various market conditions, with a strong market position and value-added product portfolio. Balchem continues to effectively manage through macroeconomic and tariff-related challenges, with growth strengthened by the "Better For You" trends in health and nutrition markets.

Carl Martin Bengtsson then opened the call for questions.